Want to see NUVB full AI Analyst Report?
Nuvation Bio (NUVB) Stock Statistics & Valuation Metrics
Total Valuation
Nuvation Bio has a market cap or net worth of $1.65B. The enterprise value is $1.74B.
- Market Cap
- $1.65B
- Enterprise Value
- $1.74B
Share Statistics
Nuvation Bio has 351,123,230 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 351,123,230
- Owned by Insiders
- 24.64%
- Owned by Institutions
- 31.45%
Financial Efficiency
Nuvation Bio’s return on equity (ROE) is -0.67 and return on invested capital (ROIC) is -40.96%.
- Return on Equity (ROE)
- -0.67
- Return on Assets (ROA)
- -0.34
- Return on Invested Capital (ROIC)
- -40.96%
- Return on Capital Employed (ROCE)
- -0.42
- Revenue Per Employee
- 206.24K
- Profits Per Employee
- -670.91K
- Employee Count
- 305
- Asset Turnover
- 0.11
- Inventory Turnover
- 0.74
Valuation Ratios
The current PE Ratio of Nuvation Bio is -11.99. Nuvation Bio’s PEG ratio is -0.25.
- PE Ratio
- -11.99
- PS Ratio
- 8.21
- PB Ratio
- 7.30
- Price to FCF
- -55.53
- Price to Operating Cash Flow
- -55.97
- PEG Ratio
- -0.25
Income Statement
In the last 12 months, Nuvation Bio had revenue of 62.90M and earned -204.63M in profits. Earnings per share was -0.60.
- Revenue
- 62.90M
- Gross Profit
- 54.46M
- Operating Income
- -213.06M
- Pretax Income
- -204.63M
- Net Income
- -204.63M
- EBITDA
- -189.21M
- Earnings Per Share (EPS)
- -0.60
Cash Flow
In the last 12 months, operating cash flow was -106.19M and capital expenditures -1.98M, giving a free cash flow of -108.17M billion.
- Operating Cash Flow
- -106.19M
- Free Cash Flow
- -108.17M
- Free Cash Flow per Share
- -0.08
Dividends & Yields
Nuvation Bio pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -7.35%
- Earnings Yield
- -9.14%
Stock Price Statistics
- Beta
- 1.63
- 52-Week Price Change
- -2.07%
- 50-Day Moving Average
- 5.59
- 200-Day Moving Average
- 5.38
- Relative Strength Index (RSI)
- 43.19
- Average Volume (3m)
- 5.38M
Important Dates
Nuvation Bio upcoming earnings date is Mar 11, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- Mar 11, 2027
- Ex-Dividend Date
- ―
Financial Position
Nuvation Bio as a current ratio of 6.95, with Debt / Equity ratio of 3.32%
- Current Ratio
- 6.95
- Quick Ratio
- 6.81
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.81
- Interest Coverage Ratio
- -15.57
Taxes
In the past 12 months, Nuvation Bio has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Nuvation Bio EV to EBITDA ratio is -12.90, with an EV/FCF ratio of -13.55.
- EV to Sales
- 9.65
- EV to EBITDA
- -12.90
- EV to Free Cash Flow
- -13.55
- EV to Operating Cash Flow
- -13.60
Balance Sheet
Nuvation Bio has $663.37M in cash and marketable securities with $468.13M in debt, giving a net cash position of $195.25M billion.
- Cash & Marketable Securities
- $663.37M
- Total Debt
- $468.13M
- Net Cash
- $195.25M
- Net Cash Per Share
- $0.56
- Tangible Book Value Per Share
- $0.59
Margins
Gross margin is 91.69%, with operating margin of -61.17%, and net profit margin of -67.38%.
- Gross Margin
- 91.69%
- Operating Margin
- -61.17%
- Pretax Margin
- -67.38%
- Net Profit Margin
- -67.38%
- EBITDA Margin
- -56.76%
- EBIT Margin
- -36.63%
Analyst Forecast
The average price target for Nuvation Bio is $13.13, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $13.13
- Price Target Upside
- 177.48% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 10
- Revenue Growth Forecast
- 1083.56%
- EPS Growth Forecast
- 30.89%
Scores
- Smart Score
- 8
- AI Score
- 49
